
Andrew J Lotery

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/258833/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	21.4	1,685
2	A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nature Genetics, 2016, 48, 134-143.	21.4	1,167
3	Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration. Ophthalmology, 2012, 119, 1399-1411.	5.2	724
4	Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet, The, 2014, 383, 1129-1137.	13.7	689
5	Seven new loci associated with age-related macular degeneration. Nature Genetics, 2013, 45, 433-439.	21.4	687
6	Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet, The, 2013, 382, 1258-1267.	13.7	623
7	A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nature Genetics, 1999, 22, 199-202.	21.4	453
8	Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nature Genetics, 2010, 42, 906-909.	21.4	357
9	Prevalence of Age-Related Macular Degeneration in Europe. Ophthalmology, 2017, 124, 1753-1763.	5.2	337
10	Missense Variations in the Fibulin 5 Gene and Age-Related Macular Degeneration. New England Journal of Medicine, 2004, 351, 346-353.	27.0	298
11	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	21.4	286
12	Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet, The, 2017, 389, 2193-2203.	13.7	279
13	Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye, 2010, 24, 1743-1756.	2.1	277
14	Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research, 2019, 73, 100770.	15.5	276
15	Genome-wide association analyses identify multiple loci associated with central corneal thickness and keratoconus. Nature Genetics, 2013, 45, 155-163.	21.4	269
16	Defining response to anti-VEGF therapies in neovascular AMD. Eye, 2015, 29, 721-731.	2.1	214
17	Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. Nature Genetics, 2014, 46, 1126-1130.	21.4	212
18	Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nature Medicine, 2020, 26, 354-359.	30.7	208

#	Article	IF	CITATIONS
19	Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. Nature Communications, 2021, 12, 1258.	12.8	196
20	Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration. Nature Genetics, 1998, 20, 328-329.	21.4	194
21	Homozygosity Mapping Reveals PDE6C Mutations in Patients with Early-Onset Cone Photoreceptor Disorders. American Journal of Human Genetics, 2009, 85, 240-247.	6.2	194
22	Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nature Genetics, 2020, 52, 160-166.	21.4	192
23	Visual Acuity after Retinal Gene Therapy for Choroideremia. New England Journal of Medicine, 2016, 374, 1996-1998.	27.0	185
24	Oxidation and age-related macular degeneration: insights from molecular biology. Expert Reviews in Molecular Medicine, 2010, 12, e34.	3.9	160
25	Age-related macular degeneration and the complement system. Immunobiology, 2012, 217, 127-146.	1.9	160
26	Association between the SERPING1 gene and age-related macular degeneration: a two-stage case–control study. Lancet, The, 2008, 372, 1828-1834.	13.7	156
27	Missense Mutations in a Retinal Pigment Epithelium Protein, Bestrophin-1, Cause Retinitis Pigmentosa. American Journal of Human Genetics, 2009, 85, 581-592.	6.2	156
28	Common genetic variants associated with open-angle glaucoma. Human Molecular Genetics, 2011, 20, 2464-2471.	2.9	152
29	An analysis of allelic variation in the ABCA4 gene. Investigative Ophthalmology and Visual Science, 2001, 42, 1179-89.	3.3	143
30	Mutation Analysis of 3 Genes in Patients With Leber Congenital Amaurosis. JAMA Ophthalmology, 2000, 118, 538.	2.4	142
31	Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nature Medicine, 2018, 24, 1507-1512.	30.7	140
32	Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 395, 294-303.	13.7	134
33	Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye, 2015, 29, 1013-1026.	2.1	133
34	Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. British Journal of Ophthalmology, 2007, 91, 1244-1246.	3.9	132
35	Evidence of association of <i>APOE</i> with age-related macular degeneration - a pooled analysis of 15 studies. Human Mutation, 2011, 32, 1407-1416.	2.5	130
36	Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. Progress in Retinal and Eye Research, 2020, 79, 100865.	15.5	125

#	Article	IF	CITATIONS
37	New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics Human Molecular Genetics, 2017, 26, ddw399.	2.9	120
38	Clinical Course, Genetic Etiology, and Visual Outcome in Cone and Cone–Rod Dystrophy. Ophthalmology, 2012, 119, 819-826.	5.2	115
39	Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. British Journal of Ophthalmology, 2007, 91, 1303-1307.	3.9	104
40	Allelic variation in the VMD2 gene in best disease and age-related macular degeneration. Investigative Ophthalmology and Visual Science, 2000, 41, 1291-6.	3.3	103
41	Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration. Pharmacoeconomics, 2008, 26, 57-73.	3.3	100
42	Variation of Codons 1961 and 2177 of the Stargardt Disease Gene Is Not Associated With Age-Related Macular Degeneration. JAMA Ophthalmology, 2001, 119, 745.	2.4	98
43	Adeno-Associated Virus Type 5: Transduction Efficiency and Cell-Type Specificity in the Primate Retina. Human Gene Therapy, 2003, 14, 1663-1671.	2.7	95
44	Ranibizumab in Myopic Choroidal Neovascularization: The 12-Month Results from the REPAIR Study. Ophthalmology, 2013, 120, 1944-1945.e1.	5.2	94
45	Spectral-Domain Optical Coherence Tomography Imaging in 67 321 Adults. Ophthalmology, 2016, 123, 829-840.	5.2	92
46	Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. Nature Communications, 2014, 5, 4883.	12.8	89
47	Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 393-406.	5.2	88
48	Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye, 2017, 31, 1-9.	2.1	87
49	Variations in Apolipoprotein E Frequency With Age in a Pooled Analysis of a Large Group of Older People. American Journal of Epidemiology, 2011, 173, 1357-1364.	3.4	85
50	Current concepts on primary open-angle glaucoma genetics: a contribution to disease pathophysiology and future treatment. Eye, 2012, 26, 355-369.	2.1	85
51	First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 337-343.	5.2	85
52	Cohort profile: design and methods in the eye and vision consortium of UK Biobank. BMJ Open, 2019, 9, e025077.	1.9	85
53	Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB–FKBPL–NOTCH4 region of chromosome 6p21.3. Human Molecular Genetics, 2012, 21, 4138-4150.	2.9	80
54	Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion. JAMA Ophthalmology, 2019, 137, 1256.	2.5	80

#	Article	IF	CITATIONS
55	Real-world experience with 0.2 î¼g/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye, 2017, 31, 1707-1715.	2.1	80
56	Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. International Journal of Epidemiology, 2012, 41, 250-262.	1.9	79
57	<i>TBK1</i> Gene Duplication and Normal-Tension Glaucoma. JAMA Ophthalmology, 2014, 132, 544.	2.5	77
58	An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye, 2008, 22, 849-854.	2.1	76
59	Photodynamic therapy for central serous chorioretinopathy. Eye, 2014, 28, 944-957.	2.1	74
60	Reduced secretion of fibulin 5 in age-related macular degeneration and cutis laxa. Human Mutation, 2006, 27, 568-574.	2.5	73
61	Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 1331-1344.	5.2	73
62	Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2012, 724, 15-36.	1.6	72
63	Interleukin-8 promoter polymorphism -251A/T is a risk factor for age-related macular degeneration. British Journal of Ophthalmology, 2008, 92, 537-540.	3.9	69
64	Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open, 2014, 4, e005094-e005094.	1.9	66
65	Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye, 2017, 31, 1697-1706.	2.1	66
66	Association of HLA Class I and Class II Polymorphisms with Age-Related Macular Degeneration. , 2005, 46, 1726.		64
67	Syphilitic acute posterior placoid chorioretinitis in nonimmunocompromised patients. Eye, 2007, 21, 1114-1119.	2.1	64
68	Progress in defining the molecular biology of age related macular degeneration. Human Genetics, 2007, 122, 219-236.	3.8	64
69	Comparison of Associations with Different Macular Inner Retinal Thickness Parameters in a Large Cohort. Ophthalmology, 2020, 127, 62-71.	5.2	64
70	Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. Ophthalmology Retina, 2020, 4, 1043-1046.	2.4	64
71	Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population. Ophthalmology, 2018, 125, 1526-1536.	5.2	62
72	A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Health Technology Assessment, 2015, 19, 1-298.	2.8	62

#	Article	IF	CITATIONS
73	CRB1 mutations may result in retinitis pigmentosa without para-arteriolar RPE preservation. Ophthalmic Genetics, 2001, 22, 163-169.	1.2	59
74	Pharmacogenetic Associations with Vascular Endothelial Growth Factor Inhibition in Participants with Neovascular Age-related Macular Degeneration in the IVAN Study. Ophthalmology, 2013, 120, 2637-2643.	5.2	59
75	Retinal Pathology and Function in a Cln3 Knockout Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis (Batten Disease). Molecular and Cellular Neurosciences, 2002, 19, 515-527.	2.2	58
76	Optimisation of polymer scaffolds for retinal pigment epithelium (RPE) cell transplantation. British Journal of Ophthalmology, 2011, 95, 563-568.	3.9	58
77	An Induced Pluripotent Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays Characteristic Features of Age-Related Macular Degeneration and Indicates a Beneficial Role for UV Light Exposure. Stem Cells, 2017, 35, 2305-2320.	3.2	58
78	Retinal pigment epithelium transplantation: concepts, challenges, and future prospects. Eye, 2015, 29, 992-1002.	2.1	56
79	Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 399-406.	5.2	55
80	Support for the involvement of complement factor I in age-related macular degeneration. European Journal of Human Genetics, 2010, 18, 15-16.	2.8	54
81	The role of epigenetics in age-related macular degeneration. Eye, 2014, 28, 1407-1417.	2.1	54
82	Risk of acute stroke in patients with retinal artery occlusion: a systematic review and meta-analysis. Eye, 2020, 34, 683-689.	2.1	53
83	Rare and common variants in extracellular matrix gene Fibrillin 2 (FBN2) are associated with macular degeneration. Human Molecular Genetics, 2014, 23, 5827-5837.	2.9	52
84	The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye, 2018, 32, 1168-1173.	2.1	52
85	Genetics and genetic testing for age-related macular degeneration. Eye, 2018, 32, 849-857.	2.1	49
86	Y chromosome mosaicism is associated with age-related macular degeneration. European Journal of Human Genetics, 2019, 27, 36-41.	2.8	49
87	The clinical effectiveness and cost-effectiveness of second-eye cataract surgery: a systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-206.	2.8	49
88	Gene Transfer to the Nonhuman Primate Retina with Recombinant Feline Immunodeficiency Virus Vectors. Human Gene Therapy, 2002, 13, 689-696.	2.7	48
89	Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye, 2013, 27, 709-715.	2.1	45
90	A systematic review to assess the â€~treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye, 2017, 31, 1337-1344.	2.1	45

#	Article	IF	CITATIONS
91	Sorsby fundus dystrophy – A review of pathology and disease mechanisms. Experimental Eye Research, 2017, 165, 35-46.	2.6	45
92	Discrepancy in current central serous chorioretinopathyÂclassification. British Journal of Ophthalmology, 2019, 103, 737-742.	3.9	45
93	Visual Function Decline Resulting from Geographic Atrophy. Ophthalmology Retina, 2020, 4, 673-688.	2.4	44
94	Correctable visual impairment in stroke rehabilitation patients. Age and Ageing, 2000, 29, 221-222.	1.6	43
95	The chemistry of retinal transplantation: the influence of polymer scaffold properties on retinal cell adhesion and control. British Journal of Ophthalmology, 2011, 95, 768-773.	3.9	43
96	Impaired Cargo Clearance in the Retinal Pigment Epithelium (RPE) Underlies Irreversible Blinding Diseases. Cells, 2018, 7, 16.	4.1	43
97	Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye, 2015, 29, 1173-1180.	2.1	42
98	Genome-wide association study of primary open angle glaucoma risk and quantitative traits. Molecular Vision, 2012, 18, 1083-92.	1.1	42
99	Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. Acta Ophthalmologica, 2022, 100, .	1.1	42
100	Localisation of a gene for central areolar choroidal dystrophy to chromosome 17p. Human Molecular Genetics, 1996, 5, 705-708.	2.9	39
101	Allelic Variation of the FRMD7 Gene in Congenital Idiopathic Nystagmus. JAMA Ophthalmology, 2007, 125, 1255.	2.4	39
102	A Review of the Molecular Genetics of Congenital Idiopathic Nystagmus (CIN). Ophthalmic Genetics, 2007, 28, 187-191.	1.2	39
103	Age-related Macular Degeneration and Modification of Systemic Complement Factor H Production Through Liver Transplantation. Ophthalmology, 2013, 120, 1612-1618.	5.2	39
104	A genome-wide association study of intra-ocular pressure suggests a novel association in the gene FAM125B in the TwinsUK cohort. Human Molecular Genetics, 2014, 23, 3343-3348.	2.9	39
105	FcÎ ³ Receptor Upregulation Is Associated With Immune Complex Inflammation in the Mouse Retina and Early Age-Related Macular Degeneration. , 2014, 55, 247.		38
106	One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. Eye, 2017, 31, 878-883.	2.1	38
107	Associations with Retinal Pigment Epithelium Thickness Measures in a Large Cohort. Ophthalmology, 2017, 124, 105-117.	5.2	38
108	An Intraocular Pressure Polygenic Risk Score Stratifies Multiple Primary Open-Angle Glaucoma Parameters Including Treatment Intensity. Ophthalmology, 2020, 127, 901-907.	5.2	37

#	Article	IF	CITATIONS
109	The Complement Component 5 Gene and Age-Related Macular Degeneration. Ophthalmology, 2010, 117, 500-511.	5.2	36
110	Photodynamic therapy for retinal capillary hemangioma. Eye, 2013, 27, 438-442.	2.1	36
111	Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma Levels Resulting in Increased Risk of Age-Related Macular Degeneration. , 2020, 61, 18.		36
112	Ambient Air Pollution Associations with Retinal Morphology in the UK Biobank. , 2020, 61, 32.		35
113	Clinical Implications of Old and New Genes for Open-Angle Glaucoma. Ophthalmology, 2011, 118, 2389-2397.	5.2	34
114	X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype. Eye, 2011, 25, 922-928.	2.1	34
115	The complexities underlying age-related macular degeneration: could amyloid beta play an important role?. Neural Regeneration Research, 2017, 12, 538.	3.0	34
116	Adaptive optics: principles and applications in ophthalmology. Eye, 2021, 35, 244-264.	2.1	33
117	Association of ambient air pollution with age-related macular degeneration and retinal thickness in UK Biobank. British Journal of Ophthalmology, 2022, 106, 705-711.	3.9	33
118	Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation?. Journal of Clinical Medicine, 2014, 3, 1234-1257.	2.4	32
119	Ophthalmic epidemiology in Europe: the "European Eye Epidemiology―(E3) consortium. European Journal of Epidemiology, 2016, 31, 197-210.	5.7	32
120	Quantification of Key Retinal Features in Early and Late Age-Related Macular Degeneration Using Deep Learning. American Journal of Ophthalmology, 2021, 226, 1-12.	3.3	32
121	Fine localisation of the gene for central areolar choroidal dystrophy on chromosome 17p Journal of Medical Genetics, 1998, 35, 770-772.	3.2	31
122	The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary. Eye, 2021, 35, 1532-1537.	2.1	31
123	Complement pathway biomarkers and age-related macular degeneration. Eye, 2016, 30, 1-14.	2.1	30
124	Association of Genetic Variants With Response to Anti–Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. JAMA Ophthalmology, 2018, 136, 875.	2.5	30
125	Glutamate excitotoxicity in glaucoma: truth or fiction?. Eye, 2005, 19, 369-370.	2.1	29
126	VEGFR2 Gene Polymorphisms and Response to Anti–Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 1563-1568.	5.2	29

#	Article	IF	CITATIONS
127	Associations with Corneal Hysteresis in a Population Cohort. Ophthalmology, 2019, 126, 1500-1510.	5.2	29
128	Association of Smoking, Alcohol Consumption, Blood Pressure, Body Mass Index, and Glycemic Risk Factors With Age-Related Macular Degeneration. JAMA Ophthalmology, 2021, 139, 1299.	2.5	29
129	Localization of complement 1 inhibitor (C1INH/SERPING1) in human eyes with age-related macular degeneration. Experimental Eye Research, 2009, 89, 767-773.	2.6	27
130	A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. Clinical Ophthalmology, 2016, 10, 87.	1.8	27
131	Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group. Eye, 2017, 31, 1582-1588.	2.1	27
132	Characteristics of p.Gln368Ter Myocilin Variant and Influence of Polygenic Risk on Glaucoma Penetrance in the UK Biobank. Ophthalmology, 2021, 128, 1300-1311.	5.2	27
133	Fungal keratitis caused by Scopulariopsis brevicaulis: successful treatment with topical amphotericin B and chloramphenicol without the need for surgical debridement British Journal of Ophthalmology, 1994, 78, 730-730.	3.9	26
134	Common spectral domain OCT and electrophysiological findings in different pattern dystrophies. British Journal of Ophthalmology, 2013, 97, 605-610.	3.9	26
135	Structural Effects of Fibulin 5 Missense Mutations Associated with Age-Related Macular Degeneration and Cutis Laxa. , 2010, 51, 2356.		25
136	Determination of a gene and environment risk model for age-related macular degeneration. British Journal of Ophthalmology, 2010, 94, 1382-1387.	3.9	25
137	United Kingdom Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group: report 4, real-world data on the impact of deprivation on the presentation of diabetic eye disease at hospital services. British Journal of Ophthalmology, 2019, 103, 837-843.	3.9	25
138	The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain. Cells, 2020, 9, 39.	4.1	25
139	Intravitreal antiâ€vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network metaâ€analysis. Acta Ophthalmologica, 2021, 99, e795-e805.	1.1	25
140	Progress in developing rodent models of age-related macular degeneration (AMD). Experimental Eye Research, 2021, 203, 108404.	2.6	24
141	Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. British Journal of Ophthalmology, 2007, 91, 1716-1717.	3.9	23
142	Developing methacrylateâ€based copolymers as an artificial Bruch's membrane substitute. Journal of Biomedical Materials Research - Part A, 2012, 100A, 2358-2364.	4.0	23
143	Oral levodopa rescues retinal morphology and visual function in a murine model of human albinism. Pigment Cell and Melanoma Research, 2019, 32, 657-671.	3.3	23
144	Epigenetics in age-related macular degeneration: new discoveries and future perspectives. Cellular and Molecular Life Sciences, 2020, 77, 807-818.	5.4	23

#	Article	IF	CITATIONS
145	Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye, 2015, 29, S1-S11.	2.1	22
146	A rare penetrant TIMP3 mutation confers relatively late onset choroidal neovascularisation which can mimic age-related macular degeneration. Eye, 2016, 30, 488-491.	2.1	22
147	Fundus autofluorescence imaging: systematic review of test accuracy for the diagnosis and monitoring of retinal conditions. Eye, 2017, 31, 995-1007.	2.1	22
148	Ex-vivo models of the Retinal Pigment Epithelium (RPE) in long-term culture faithfully recapitulate key structural and physiological features of native RPE. Tissue and Cell, 2017, 49, 447-460.	2.2	22
149	Multi-trait genome-wide association study identifies new loci associated with optic disc parameters. Communications Biology, 2019, 2, 435.	4.4	22
150	Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. British Journal of Ophthalmology, 2020, 104, 493-499.	3.9	22
151	Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmology Retina, 2018, 2, 118-127.	2.4	21
152	Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study. Eye, 2021, 35, 592-600.	2.1	21
153	Age-Related Macular Degeneration Is Associated with the HLA-Cw*0701 Genotype and the Natural Killer Cell Receptor AA Haplotype. , 2008, 49, 5077.		20
154	SUCCESSFUL TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO SORSBY FUNDUS DYSTROPHY WITH INTRAVITREAL BEVACIZUMAB. Retinal Cases and Brief Reports, 2011, 5, 132-135.	0.6	20
155	Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review. Eye, 2014, 28, 1399-1406.	2.1	20
156	The Decreasing Prevalence of Nonrefractive Visual Impairment in Older Europeans. Ophthalmology, 2018, 125, 1149-1159.	5.2	20
157	Retinal asymmetry in multiple sclerosis. Brain, 2021, 144, 224-235.	7.6	20
158	Biodegradable poly(αâ€hydroxy ester) blended microspheres as suitable carriers for retinal pigment epithelium cell transplantation. Journal of Biomedical Materials Research - Part A, 2010, 95A, 1233-1243.	4.0	19
159	Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept. Ophthalmology Retina, 2019, 3, 567-575.	2.4	19
160	Fine-scale linkage disequilibrium mapping of age-related macular degeneration in the complement factor H gene region. British Journal of Ophthalmology, 2007, 91, 966-970.	3.9	18
161	Prevalence of myocilin gene mutations in a novel UK cohort of POAG patients. Eye, 2010, 24, 328-333.	2.1	18
162	The Alzheimer's-related amyloid beta peptide is internalised by R28 neuroretinal cells and disrupts the microtubule associated protein 2 (MAP-2). Experimental Eve Research, 2016, 153, 110-121	2.6	18

#	Article	IF	CITATIONS
163	Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience. Scientific Reports, 2021, 11, 4800.	3.3	18
164	Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. Eye, 2022, 36, 1012-1018.	2.1	18
165	Complement factor I and age-related macular degeneration. Molecular Vision, 2014, 20, 1253-7.	1.1	18
166	Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clinical Ophthalmology, 2017, Volume 11, 1957-1966.	1.8	17
167	A lasered mouse model of retinal degeneration displays progressive outer retinal pathology providing insights into early geographic atrophy. Scientific Reports, 2019, 9, 7475.	3.3	17
168	Myocilin Mutations in Patients With Normal-Tension Glaucoma. JAMA Ophthalmology, 2019, 137, 559.	2.5	17
169	Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration. Ophthalmology, 2021, 128, 1736-1747.	5.2	17
170	<p>Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration</p> . Biologics: Targets and Therapy, 2020, Volume 14, 83-94.	3.2	17
171	Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-254.	2.8	17
172	Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis. Atherosclerosis, 2006, 188, 213-214.	0.8	16
173	Coat's-like exudation in rhodopsin retinitis pigmentosa: successful treatment with an intravitreal dexamethasone implant. Eye, 2014, 28, 449-451.	2.1	16
174	The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD. Eye, 2022, 36, 2192-2199.	2.1	16
175	Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins. British Journal of Ophthalmology, 2007, 91, 1729-1730.	3.9	15
176	A multi-paradigm, whole system view of health and social care for age-related macular degeneration. , 2012, , .		15
177	Variation in complement component C1 inhibitor in age-related macular degeneration. Immunobiology, 2012, 217, 251-255.	1.9	15
178	Oxidative Stress and Dysfunctional Intracellular Traffic Linked to an Unhealthy Diet Results in Impaired Cargo Transport in the Retinal Pigment Epithelium (RPE). Molecular Nutrition and Food Research, 2019, 63, e1800951.	3.3	15
179	Socio-economic status and outcomes for patients with age-related macular degeneration. Eye, 2019, 33, 1224-1231.	2.1	15
180	Monitoring for retinal toxicity in patients taking hydroxychloroquine and chloroquine. Rheumatology, 2019, 58, 3-4.	1.9	15

#	Article	IF	CITATIONS
181	The Molecular Genetics of Congenital Idiopathic Nystagmus. Seminars in Ophthalmology, 2006, 21, 87-90.	1.6	14
182	Infantile nystagmus and late onset ataxia associated with a CACNA1A mutation in the intracellular loop between s4 and s5 of domain 3. Eye, 2009, 23, 2251-2255.	2.1	14
183	Dear reader,. Eye, 2009, 23, 1-1.	2.1	14
184	A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility. Journal of Clinical Neuroscience, 2012, 19, 65-70.	1.5	14
185	Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA. Eye, 2015, 29, 380-387.	2.1	14
186	From compliment to insult: genetics of the complement system in physiology and disease in the human retina. Human Molecular Genetics, 2017, 26, R51-R57.	2.9	14
187	The rare <i>C9</i> P167S risk variant for age-related macular degeneration increases polymerization of the complement cascade. Human Molecular Genetics, 2021, 30, 1188-1199.	2.9	14
188	Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study. PLoS ONE, 2015, 10, e0128403.	2.5	14
189	Macular thickness varies with age-related macular degeneration genetic risk variants in the UK Biobank cohort. Scientific Reports, 2021, 11, 23255.	3.3	14
190	HLA and eye disease: a synopsis. International Journal of Immunogenetics, 2005, 32, 333-342.	1.8	13
191	Frmd7 expression in developing mouse brain. Eye, 2010, 24, 165-169.	2.1	13
192	Can genetic risk information for age-related macular degeneration influence motivation to stop smoking? A pilot study. Eye, 2012, 26, 109-118.	2.1	13
193	A convenient protocol for establishing a human cell culture model of the outer retina F1000Research, 2018, 7, 1107.	1.6	13
194	Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. Eye, 2019, 33, 295-303.	2.1	13
195	3D-Reconstructed Retinal Pigment Epithelial Cells Provide Insights into the Anatomy of the Outer Retina. International Journal of Molecular Sciences, 2020, 21, 8408.	4.1	13
196	Characterisation of mouse limbal neurosphere cells: a potential cell source of functional neurons. British Journal of Ophthalmology, 2012, 96, 1431-1437.	3.9	12
197	Occult giant cell (temporal) arteritis presenting with bilateral sixth and unilateral fourth nerve palsies. Eye, 1998, 12, 1014-1016.	2.1	11
198	Fibulin 5 Forms a Compact Dimer in Physiological Solutions. Journal of Biological Chemistry, 2009, 284, 25938-25943.	3.4	11

#	Article	IF	CITATIONS
199	What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?. BMJ, The, 2014, 349, g6887-g6887.	6.0	11
200	Rare complement factor I variants associated with reduced macular thickness and age-related macular degeneration in the UK Biobank. Human Molecular Genetics, 2022, 31, 2678-2692.	2.9	11
201	Long-term survival in a case of bilateral diffuse uveal melanocytic proliferation. Eye, 2011, 25, 1385-1386.	2.1	10
202	Phenotype/genotype correlation in a case series of Stargardt's patients identifies novel mutations in the ABCA4 gene. Eye, 2013, 27, 1316-1319.	2.1	10
203	In vitro stem cell modelling demonstrates a proofâ€ofâ€concept for excess functional mutant TIMP3 as the cause of S orsby f undus d ystrophy. Journal of Pathology, 2020, 252, 138-150.	4.5	10
204	Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis. European Journal of Ophthalmology, 2021, 31, 2496-2504.	1.3	10
205	Socioeconomic risk factors and age-related macular degeneration in the UK Biobank study. BMJ Open Ophthalmology, 2021, 6, e000585.	1.6	10
206	Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment, 2021, 25, 1-196.	2.8	10
207	A High Fat "Westernâ€style―Diet Induces AMD‣ike Features in Wildtype Mice. Molecular Nutrition and Food Research, 2022, 66, e2100823.	3.3	10
208	The cost-effectiveness of second-eye cataract surgery in the UK. Age and Ageing, 2015, 44, 1026-1031.	1.6	9
209	Gene therapy for RPE65 -mediated inherited retinal dystrophy completes phase 3. Lancet, The, 2017, 390, 823-824.	13.7	9
210	Multicolor imaging in the diagnosis and follow up of type 2 acute macular neuroretinopathy. Eye, 2017, 31, 127-131.	2.1	9
211	A small gene sequencing panel realises a high diagnostic rate in patients with congenital nystagmus following basic phenotyping. Scientific Reports, 2019, 9, 13229.	3.3	9
212	Multimodal imaging of late-onset retinal degeneration complicated by bilateral choroidal neovascularization. Eye, 2019, 33, 1020-1027.	2.1	9
213	AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization. Molecular Therapy - Methods and Clinical Development, 2019, 13, 86-98.	4.1	9
214	COVID19 and ophthalmology: a brief summary of the literature. Eye, 2020, 34, 1200-1202.	2.1	9
215	Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade. Ophthalmology Retina, 2021, 5, e11-e22.	2.4	9
216	Challenges in studying geographic atrophy (GA) age-related macular degeneration: the potential of a new mouse model with GA-like features. Neural Regeneration Research, 2020, 15, 863.	3.0	9

#	Article	IF	CITATIONS
217	Developing and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration—the PINNACLE trial protocol. Eye, 2023, 37, 1275-1283.	2.1	9
218	Retinal pigment epithelial tear following intravitreal bevacizumab for choroidal neovascular membrane due to age-related macular degeneration. British Journal of Ophthalmology, 2007, 91, 977-978.	3.9	8
219	Vitamin A deficiency-related retinopathy after bariatric surgery. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 941-943.	1.9	8
220	Comprehensive sequencing of the myocilin gene in a selected cohort of severe primary open-angle glaucoma patients. Scientific Reports, 2019, 9, 3100.	3.3	8
221	Pentosan Polysulfate Maculopathy—Prescribers Should Be Aware. JAMA Ophthalmology, 2020, 138, 900.	2.5	8
222	Multimodal Imaging in the Management of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. Journal of Clinical Medicine, 2020, 9, 1934.	2.4	8
223	Oligomeric AÎ ² 1-42 Induces an AMD-Like Phenotype and Accumulates in Lysosomes to Impair RPE Function. Cells, 2021, 10, 413.	4.1	8
224	Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. Human Mutation, 2021, 42, 1139-1152.	2.5	8
225	Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years. Eye, 2022, 36, 72-77.	2.1	8
226	Associations of Alcohol Consumption and Smoking With Disease Risk and Neurodegeneration in Individuals With Multiple Sclerosis in the United Kingdom. JAMA Network Open, 2022, 5, e220902.	5.9	8
227	Epigenetic Age Acceleration Is Not Associated with Age-Related Macular Degeneration. International Journal of Molecular Sciences, 2021, 22, 13457.	4.1	8
228	Electrophysiology findings in a large family with central areolar choroidal dystrophy. Documenta Ophthalmologica, 1998, 97, 103-119.	2.2	7
229	Retinitis pigmentosa and bilateral cystoid macular oedema in a patient heterozygous for the RIM1 mutation previously associated with cone-rod dystrophy 7. Ophthalmic Genetics, 2017, 38, 178-182.	1.2	7
230	Joint recommendations for retinal screening in long-term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018. British Journal of Dermatology, 2018, 179, 995-996.	1.5	7
231	How to set up a Hydroxychloroquine Retinopathy Screening Service. Eye, 2019, 33, 1679-1682.	2.1	7
232	An In-Vitro Cell Model of Intracellular Protein Aggregation Provides Insights into RPE Stress Associated with Retinopathy. International Journal of Molecular Sciences, 2020, 21, 6647.	4.1	7
233	Fixed bimonthly aflibercept in naÃ ⁻ ve and switched neovascular age-related macular degeneration patients: one year outcomes. International Journal of Ophthalmology, 2016, 9, 1156-62.	1.1	7
234	Paucimorphic Alleles versus Polymorphic Alleles and Rare Mutations in Disease Causation: Theory, Observation and Detection. Current Genomics, 2004, 5, 431-438.	1.6	7

#	Article	IF	CITATIONS
235	Chlamydia infection status, genotype, and age-related macular degeneration. Molecular Vision, 2012, 18, 29-37.	1.1	7
236	Genetics update of macular diseases. Ophthalmology Clinics of North America, 2002, 15, 459-465.	1.8	6
237	The cheaper drug, bevacizumab, should be referred to NICE. BMJ: British Medical Journal, 2007, 334, 381.3-382.	2.3	6
238	Bilateral cataract surgery with intraocular lens implant in a captive western lowland gorilla. Journal of Medical Primatology, 2017, 46, 252-255.	0.6	6
239	Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. Pharmacoeconomics, 2021, 39, 913-927.	3.3	6
240	Fine mapping of the X-linked recessive congenital idiopathic nystagmus locus at Xq24-q26.3. Molecular Vision, 2006, 12, 1211-6.	1.1	6
241	Evaluating a Causal Relationship between Complement Factor I Protein Level and Advanced Age-Related Macular Degeneration Using Mendelian Randomization. Ophthalmology Science, 2022, 2, 100146.	2.5	6
242	Radiotherapy for age-related macular degeneration: no more pilot studies please. Eye, 2005, 19, 1137-1141.	2.1	5
243	Cystoid macular oedema successfully treated by cryotherapy in retinitis pigmentosa with Coats'-like retinal exudation. Eye, 2011, 25, 821-822.	2.1	5
244	Sorsby fundus dystrophy with polypoidal choroidal vasculopathy: Extending TIMP3 phenotypes. Clinical and Experimental Ophthalmology, 2019, 47, 1214-1218.	2.6	5
245	A novel, wearable, electronic visual aid to assist those with reduced peripheral vision. PLoS ONE, 2019, 14, e0223755.	2.5	5
246	Evaluation of Pro-re-Nata (PRN) and Treat and Extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy. European Journal of Ophthalmology, 2020, 30, 26-33.	1.3	5
247	The integration of genomics into clinical ophthalmic services in the UK. Eye, 2020, 34, 993-996.	2.1	5
248	An objective method of diagnosing hydroxychloroquine maculopathy. Eye, 2021, 35, 1922-1929.	2.1	5
249	Adult Limbal Neurosphere Cells: A Potential Autologous Cell Resource for Retinal Cell Generation. PLoS ONE, 2014, 9, e108418.	2.5	5
250	Long term follow-up of a family with GUCY2D dominant cone dystrophy. International Journal of Ophthalmology, 2018, 11, 1945-1950.	1.1	5
251	latrogenic acute angle closure glaucoma masked by general anaesthesia and intensive care. Ulster Medical Journal, 1995, 64, 178-80.	0.2	5
252	Generation of a Cone Photoreceptor-specific GNGT2 Reporter Line in Human Pluripotent Stem Cells. Stem Cells, 2022, 40, 190-203.	3.2	5

#	Article	IF	CITATIONS
253	Subretinal drusenoid deposits as a biomarker of age-related macular degeneration progression via reduction of the choroidal vascularity index. Eye, 2023, 37, 1365-1370.	2.1	5
254	Treatment and long term follow up of a capillary angioma of the optic disc. International Ophthalmology, 1995, 19, 129-132.	1.4	4
255	Bevacizumab: a new way of doing business?. Eye, 2006, 20, 985-987.	2.1	4
256	Progress in understanding and treating age-related macular degeneration. Eye, 2008, 22, 739-741.	2.1	4
257	Morning glory with serous macular detachment responds to oral acetazolamide. Eye, 2010, 24, 1732-1733.	2.1	4
258	Characterization of the Frmd7 Knock-Out Mice Generated by the EUCOMM/COMP Repository as a Model for Idiopathic Infantile Nystagmus (IIN). Genes, 2020, 11, 1157.	2.4	4
259	Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study. Eye, 2022, 36, 1656-1661.	2.1	4
260	Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-82.	0.7	4
261	Long-term Retinal Morphology and Functional Associations in Treated Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2022, 6, 664-675.	2.4	4
262	New recommendations for retinal monitoring in hydroxychloroquine users: baseline testing is no longer supported. British Journal of Dermatology, 2021, 185, 435-438.	1.5	3
263	Animal models of age-related macular degeneration. Drug Discovery Today: Disease Models, 2013, 10, e181-e187.	1.2	2
264	Oxidative Damage and Macular Degeneration. , 2014, , 3625-3653.		2
265	Requirement for retinal screening in patients taking hydroxychloroquine and chloroquine. British Journal of General Practice, 2018, 68, 120.2-120.	1.4	2
266	Tolperisone, a centrally-acting muscle relaxant: a possible cause of macular haemorrhage. Eye, 2020, 34, 1380-1381.	2.1	2
267	Eplerenone for chronic central serous chorioretinopathy – Authors' reply. Lancet, The, 2020, 396, 1557-1558.	13.7	2
268	Monitoring for hydroxychloroquine retinopathy. Eye, 2020, 34, 1301-1302.	2.1	2
269	Can we classify central serous chorioretinopathy better? Yes we can. Eye, 2022, 36, 487-487.	2.1	2
270	Intravitreal dexamethasone implant versus anti-vascular endothelial growth factor therapy combined with cataract surgery in patients with diabetic macular oedema: a systematic review with meta-analysis. Eye, 2022, 36, 2239-2246.	2.1	2

#	Article	IF	CITATIONS
271	Estimating excess visual loss from neovascular age-related macular degeneration in the UK during the COVID-19 pandemic: a retrospective clinical audit and simulation model. BMJ Open, 2022, 12, e057269.	1.9	2
272	Bevacizumab: a new way of doing business?. Eye, 2007, 21, 891-891.	2.1	1
273	All change. Eye, 2008, 22, 2-2.	2.1	1
274	Improving cellular adhesion on scaffolds for transplantation: synthesising a poly(MMA-co-PEGM) network. Journal of Materials Chemistry B, 2013, 1, 6627.	5.8	1
275	EYE: a journal to be proud of. Eye, 2013, 27, 575-576.	2.1	1
276	Response to â€~Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA'. Eye, 2015, 29, 1113-1114.	2.1	1
277	New ideas for glaucoma. Eye, 2015, 29, 1241-1241.	2.1	1
278	A Genome-Wide Complement for Central Serous Chorioretinopathy. JAMA Ophthalmology, 2018, 136, 1136.	2.5	1
279	Bevacizumab: a new way of doing business. Part 2. Eye, 2019, 33, 519-520.	2.1	1
280	Baseline retinal testing is no longer recommended for hydroxychloroquine users in the United Kingdom. Rheumatology, 2021, 60, 2037-2039.	1.9	1
281	Age-related macular degeneration – biomarkers and therapies. Regenerative Medicine, 2021, 16, 431-434.	1.7	1
282	Irish college of ophthalmologists. Irish Journal of Medical Science, 1993, 162, 531-533.	1.5	0
283	Cenetic variants within chromosome 4q28.3 are not reproducibly associated with Age-related Macular Degeneration (AMD). Acta Ophthalmologica, 2011, 89, e603-e604.	1.1	0
284	Reply to â€~Comments on Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants'. Eye, 2016, 30, 1023-1024.	2.1	0
285	Thank you and goodbye!. Eye, 2017, 31, 1634-1634.	2.1	0
286	Reply to: â€~Comment on: â€~One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'. Eye, 2018, 32, 479-481.	2.1	0
287	AMD Risk Alleles Are Not Implicated in Age-Related Macular Degeneration in Patients with Liver Transplantation. Ophthalmology Retina, 2018, 2, 872-874.	2.4	0
288	Macular toxicity secondary to occupational exposure to gold melting. Eye, 2019, 33, 1667-1669.	2.1	0

#	Article	IF	CITATIONS
289	Retinal artery occlusion and risk of stroke. Journal of Vascular Surgery, 2020, 72, 1832-1833.	1.1	0
290	Hydroxychloroquine retinopathy: screening and genetics. Eye, 2021, 35, 1522-1523.	2.1	0
291	Reply to: †Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'. Eye, 2021, 35, 3448.	2.1	0
292	At What Age Does Age-Related Macular Degeneration Start?. JAMA Ophthalmology, 2021, 139, 1226.	2.5	0